Search research articles
Contact Us
Filters
Showing results (431-440 of 448) with videos related to
Page
of 45
Sort By:
Nature Communications
|
February 5, 2026
Paper-based fluorescent assay for blood typing and antibody titer determination using long-term ambient-stored bioengineered RBCs
Yuxuan Li, Yulong Zhang, Shengqiang Liang, et al.
The Science of the Total Environment
|
July 6, 2023
Contribution of the bacterial community of poorly fermented oat silage to biogas emissions on the Qinghai Tibetan Plateau
Chaosheng Liao, Binbin Na, Xiaolong Tang, et al.
Huan Jing Ke Xue= Huanjing Kexue
|
July 3, 2018
[Particle Size Distribution and Human Health Risk Assessment of Heavy Metals in Atmospheric Particles from Beijing and Xinxiang During Summer]
Xin Zhang, Xiao-Man Zhao, Xue-Jie Meng, et al.
Annals of Hematology
|
September 23, 2024
Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study
Weijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Nutrition & Metabolism
|
January 3, 2024
Deficiency of Trex1 leads to spontaneous development of type 1 diabetes
Jiang-Man Zhao, Zhi-Hui Su, Qiu-Ying Han, et al.
Annals of Hematology
|
September 3, 2024
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
Weijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Annals of Hematology
|
May 23, 2025
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study
Weijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Cancer Research
|
February 6, 2023
HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression
Yufei Wang, Man Zhao, Lina Zhao, et al.
Journal of Medicinal Chemistry
|
February 2, 2026
Arylidene-Thiazoldione Scaffold Acts as the E3 Ligand of DCAF11 for PROTAC Design
Jinyi Liang, Yuyang Liu, Man Zhao, et al.
Journal of Hepatology
|
October 18, 2025
HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses
Hongfeng Yuan, Lina Zhao, Guang Yang, et al.
Page
of 45
Search research articles
Search
Showing results (431-440 of 448) with videos related to
Sort By:
Page
of 45
Nature Communications
|
February 5, 2026
Paper-based fluorescent assay for blood typing and antibody titer determination using long-term ambient-stored bioengineered RBCs
Yuxuan Li, Yulong Zhang, Shengqiang Liang, et al.
The Science of the Total Environment
|
July 6, 2023
Contribution of the bacterial community of poorly fermented oat silage to biogas emissions on the Qinghai Tibetan Plateau
Chaosheng Liao, Binbin Na, Xiaolong Tang, et al.
Huan Jing Ke Xue= Huanjing Kexue
|
July 3, 2018
[Particle Size Distribution and Human Health Risk Assessment of Heavy Metals in Atmospheric Particles from Beijing and Xinxiang During Summer]
Xin Zhang, Xiao-Man Zhao, Xue-Jie Meng, et al.
Annals of Hematology
|
September 23, 2024
Correction to: Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS study
Weijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Nutrition & Metabolism
|
January 3, 2024
Deficiency of Trex1 leads to spontaneous development of type 1 diabetes
Jiang-Man Zhao, Zhi-Hui Su, Qiu-Ying Han, et al.
Annals of Hematology
|
September 3, 2024
Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study
Weijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Annals of Hematology
|
May 23, 2025
Health-related quality of life with daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible patients with newly diagnosed multiple myeloma: analysis of the phase 3 OCTANS study
Weijun Fu, Soo-Mee Bang, Honghui Huang, et al.
Cancer Research
|
February 6, 2023
HBx-Induced HSPA8 Stimulates HBV Replication and Suppresses Ferroptosis to Support Liver Cancer Progression
Yufei Wang, Man Zhao, Lina Zhao, et al.
Journal of Medicinal Chemistry
|
February 2, 2026
Arylidene-Thiazoldione Scaffold Acts as the E3 Ligand of DCAF11 for PROTAC Design
Jinyi Liang, Yuyang Liu, Man Zhao, et al.
Journal of Hepatology
|
October 18, 2025
HBx-induced HSPB1 is a potential therapeutic target owing to its modulation of HBV cccDNA and hepatic immune responses
Hongfeng Yuan, Lina Zhao, Guang Yang, et al.
Page
of 45